Gang Wu

Gang Wu

Auto-generated profile, based on publicly available information

Gang Wu

Department of Pharmacy, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Linhai, Zhejiang, 317000, PR China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2024 in Seizure: European Journal of Epilepsy
Verified
Journal Article
Open access
ZHZhimin He
Zhimin He
CLCuimin Liu
Cuimin Liu
LLLin Lin
Lin Lin
GFGuowen Feng
Guowen Feng
GWGang Wu
Gang Wu
Levetiracetam is a relatively new and widely utilized anti-seizure medication; however, limited information is available regarding its adverse effects. This study aims to thoroughly investigate, evaluate, and present evidence on the safety profile of Levetiracetam, relying on data from the FDA Adverse Event Reporting System (FAERS) database to facilitate informed clinical decision-making. We employed various statistical measures, including Reporting Odds Ratio (ROR), Proportionate Reporting Ratio (PRR), and analysis by the Medicines and Healthcare Products Regulatory Agency (MHRA), to identify signals of adverse reactions associated with Levetiracetam. Positive signals consistent with Designated Medical Event (DME) were singled out for focused comparison and discussion. The analysis of 26,182 adverse events linked to Levetiracetam as the primary suspected drug revealed 692 positive signals spanning 22 System Organ Classes (SOCs). Nervous system disorders were the most frequently reported, followed by psychiatric disorders, and general disorders and administration site conditions. 11 positive signals consistent with Preferred Terms (PTs) in DME were identified, predominantly concentrated in 6 SOCs. Among these, rhabdomyolysis, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS) exhibited relatively large values of A, ROR, and Chi-squared. Additionally, PTs related to spontaneous abortion, drug interaction, urethral atresia, ventricular septal defect, and atrial septal defect showed significant strength. The study indicates that Levetiracetam carries a potential risk of causing rhabdomyolysis, SJS, TEN, DRESS as well as spontaneous abortion. Signals related to drug interaction, urethral atresia, ventricular septal defect, and atrial septal defect warrant heightened attention in clinical use.

17 September 2022 in The Neurologist
Verified
Journal Article
Open access
GWGang Wu
Gang Wu
YSYuguang Mbbs Shen
Yuguang Mbbs Shen
FZFeng Mbbs Zhu
Feng Mbbs Zhu
WTWeiwei Mbbs Tao
Weiwei Mbbs Tao
YZYuanlin Zhou
Yuanlin Zhou
HJHuihua Mbbs Jiang
Huihua Mbbs Jiang
Introduction: The mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome is a matrilineal hereditary multisystem disease caused by mutations in the mitochondrial DNA. Although the initial diagnostic criteria correlate with a range of clinical phenotypes, including clinical onset after the age of 40, there is still lack of a unified single diagnostic standard for MELAS. Case Report: A 71-year-old female patient with recurrent stroke was reported. Magnetic resonance imaging showed a cerebral gyrus-like diffusion weighted imaging high signal lesion in the parietal-occipital lobe and the area of this lesion expanded with disease progression. The MRS result showed significantly inverted Lac/Lip peaks. The nucleic acid sequencing result displayed a MT-TWm.5541C>T mutation, and a 12.86% mutation rate in the blood sample. The patient had a 6-year history of type 2 diabetes. Conclusion: Patients with the MELAS syndrome may present with a variety of clinical manifestations. Our data demonstrated that, for patients with atypical cerebral infarction and suspected MELAS syndrome, gene sequencing and muscle biopsy should be performed in time. This case provides a reference for the diagnostic criteria of MELAS syndrome.

1 August 2019
Verified
Conference Paper
Closed access
GWGang Wu
Gang Wu
PYPeng Yang
Peng Yang
JLJingjing Luo
Jingjing Luo
LYLi Yu
Li Yu
The control mechanism of SDN tends to be distributed when the network scale expands. As the number of controllers grows, how to efficiently respond to network events in a timely fashion becomes challenging. Specifically, distributed controllers should reach a consensus on network states before making a network update decision in legacy consensus algorithm, which causes unexpected latency. While eventual correctness algorithms relies on Gossip schemes for fast recovery from network failures, leading to highly redundant controller responses when handling one single network event. In this paper, we aim at developing efficient control algorithm that eliminates unnecessary controller processing, facilitating rapid response to network events. To this end, we design a joint controller selection and message forwarding scheme, which identifies a subset of controllers for control message dissemination. An optimization problem is formulated with the objective of minimizing the total control overhead, which is found to be reducible to the K-center problem. Simulation results show that our method reduces up to 61% of the control overhead compared with legacy benchmarks.